Comparison of Medical Therapy, Pacing and Defibrillation in Heart Failure

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00180258
Recruitment Status : Completed
First Posted : September 16, 2005
Last Update Posted : January 25, 2007
Information provided by:
Boston Scientific Corporation

September 9, 2005
September 16, 2005
January 25, 2007
January 2000
Not Provided
Combination of all-cause mortality and first hospitalization (time to first event), where all-cause mortality is defined as death from all causes.
Same as current
Complete list of historical versions of study NCT00180258 on Archive Site
Total survival for both the CONTAK CD and CONTAK TR CHFDs when used in conjunction with pharmacologic therapy.
Same as current
Not Provided
Not Provided
Comparison of Medical Therapy, Pacing and Defibrillation in Heart Failure
Comparison of Medical Therapy, Pacing and Defibrillation in Heart Failure
The purpose of this study is to determine whether combined mortality and hospitalization in heart failure patients receiving optimal pharmacologic therapy can be reduced by combining optimal pharmacologic therapy and 1) biventricular pacing therapy alone or 2) biventricular pacing with defibrillation.
Evaluation of new therapies for the treatment of heart failure should address mortality, morbidity, hospitalization, and cardiac symptoms and function when compared to standard pharmacologic therapy. The COMPANION trial is designed to address all of these objectives. This clinical investigation is an open-label, prospective, multi-center, randomized clinical trial. Every patient enrolled in the study is to be prescribed to optimal pharmacologic heart failure therapy, as tolerated, regardless of randomization.
Phase 2
Phase 3
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Congestive Heart Failure
Device: Cardiac Resynchronization Therapy with & without defibrillator
Not Provided

*   Includes publications given by the data provider as well as publications identified by Identifier (NCT Number) in Medline.
Same as current
December 2002
Not Provided

Inclusion Criteria:

  • Moderate or severe heart failure, defined as symptomatic heart failure for at least six months with NYHA Class III or IV symptoms at the time of enrollment, AND at least one of the following events in the previous 12 months:
  • Hospitalization for heart failure management
  • Outpatient visit in which intravenous (IV) inotropes or vasoactive infusion were administered continuously for at least 4 hours
  • Emergency room visit of at least twelve hours duration in which IV heart failure medications were administered (including diuretics)
  • QRS > or = 120 ms and PR interval > 150 ms from any two leads of a 12-lead ECG
  • Left ventricular ejection fraction < or = 35%
  • Left ventricular end diastolic dimension > or = 60 mm (required only if LVEF measured by echo) or > 3.0 cm/m2 [The cm/m2 is calculated by LVEDD (in cm) divided by BSA (body surface area)].
  • Age > or = 18 years
  • Optimal pharmacologic therapy for heart failure

Exclusion Criteria:

  • Unable or unwilling to undergo device implant and follow-up testing
  • Meet the general indications for an implantable cardioverter defibrillator
  • Meet the general indications for antibradycardia pacing
  • Expected to receive a heart transplant in the next six months
  • Chronic, medically refractory atrial tachyarrhythmias
  • Unexplained syncope
  • Myocardial infarction within 60 days of randomization
  • History of non-compliance with oral heart failure therapy
  • Progressive or unstable angina
  • Uncontrolled blood pressure: Systolic BP > 160 mm Hg or < 85 mm Hg or diastolic BP > 90 mm Hg
  • Patients with a hypersensitivity to a 0.7 mg nominal dose of dexamethasone acetate
  • Surgically uncorrected primary valvular heart disease
  • Coronary artery disease (CAD) in which surgical or percutaneous correction is recent (within 60 days of randomization)
  • Women who are pregnant or not using medically acceptable birth control
  • Hypertrophic obstructive cardiomyopathy
  • Amyloid disease
  • Hospitalization for heart failure or IV inotropic or vasoactive therapy in excess of 4 hours in the 30 days prior to enrollment
  • Have a tricuspid prosthesis
  • Involved in any other investigational studies
  • Life expectancy < 6 months due to any other medical conditions
Sexes Eligible for Study: All
18 Years and older   (Adult, Senior)
Contact information is only displayed when the study is recruiting subjects
United States
Not Provided
Not Provided
Not Provided
Not Provided
Boston Scientific Corporation
Not Provided
Not Provided
Boston Scientific Corporation
January 2007

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP